EMA Approves KalVista's Ekterly, the First Oral On-Demand Therapy for Hereditary Angioedema
First Oral On-Demand Treatment Approved in Europe
The European Medicines Agency (EMA) has granted final approval for Ekterly (sebetralstat) from KalVista Pharmaceuticals (KVSF) for the treatment of Hereditary Angioedema (HAE). Ekterly is a small-molecule compound that targets and inhibits plasma kallikrein, making it the first oral on-demand option for the acute treatment of HAE in adolescents and adults aged 12 years and older. Existing treatments have largely relied on intravenous or subcutaneous formulations, which significantly limited patient convenience. This approval of an oral medication is considered a groundbreaking milestone that will revolutionize the treatment paradigm for HAE.
Efficacy and Safety Demonstrated Through Phase 3 Clinical Data
The core basis for this European approval lies in the successful demonstration of efficacy in the global Phase 3 KONFIDENT study. The clinical results showed that the Ekterly 300mg group reduced the median time to symptom relief to 1.61 hours, a statistically significant improvement compared to the 6.72 hours observed in the placebo group (p<0.0001). Furthermore, no serious adverse events (SAEs) related to the treatment were reported during the clinical trial, and there were no cases of discontinuation due to adverse reactions, demonstrating high safety and excellent tolerability.
Securing a Strong Competitive Edge in an Injectable-Centric Market
The global HAE treatment market is currently estimated at $3 billion to $4 billion, with injectable formulations such as Takeda's Firazyr (icatibant) being the standard of care for acute attacks. BioCryst's Orladeyo (berotralstat) has pioneered the market as an oral prophylactic therapy, but Ekterly is the only oral treatment available for immediate response to acute attacks. Therefore, it is expected to rapidly absorb patients who experience discomfort or difficulty with injections and self-administration, thereby reshaping the acute treatment market, which is currently dominated by injectable therapies.
Establishing a Direct Sales Presence in Europe and Maximizing Global M&A Value
KalVista has chosen a strategy of directly commercializing Ekterly in the European market, starting in Germany, without forming external partnerships. Subsequently, in April 2026, Chiesi Group, a global pharmaceutical company, agreed to acquire KalVista for approximately $1.9 billion (USD), which is expected to further strengthen the global distribution network and marketing synergies for Ekterly. Now that regulatory hurdles have been cleared, the key variables for initial revenue growth will be the listing of Ekterly on national health insurance formularies and price negotiations with health authorities in each European country.
Ekterly is the first oral on-demand therapy that can replace the existing acute treatment standard of care, which is primarily based on intravenous or subcutaneous injections, in the global HAE treatment market, estimated at approximately $3 billion to $4 billion annually. The rapid symptom relief data of 1.61 hours demonstrated in the Phase 3 (KONFIDENT) trial, along with its excellent safety profile, provides a clear competitive advantage over existing injectable competitors such as Takeda's Firazyr. In particular, the agreement for Chiesi Group to acquire KalVista for approximately $1.9 billion in April 2026, shortly after the European approval, will further accelerate the development of global distribution networks and subsequent pipeline development. However, in the initial launch phase, the speed of price negotiations and listing on national health insurance formularies in each European country will be the key determinants of short-term revenue growth.
Source: EMA (ema)